In what might become a new scandal for Novartis (NVS), federal investigators recently demanded information from the drug maker about the pricing and marketing of one of its biggest-selling drugs, and the focus of the probe includes compensation paid to physicians.
Last month, the U.S. Department of Justice issued a civil investigative demand about Entresto, a heart failure drug that generated $924 million in sales in the third quarter, a 46% gain. The demand was disclosed by the company in a regulatory filing, but further details were not made available (see page 36). Novartis is “working with the government to provide the requested information,” a spokeswoman wrote us.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
